This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): MN-IC, Bayer HuCAL-derived ADC
Description: This collaborative drug between Bayer and Morphosys is a HuCAL-derived antibody-drug conjugate (ADC) in the therapeutic area of oncology. The program is directed against the target molecule MN, also known as Carbonic Anhydrase or CA IX, a tumor associated antigen expressed in many tumor types under hypoxic conditions. In this program, the HuCAL-derived antibody-drug conjugate incorporates technology licensed to Bayer Schering Pharma from Seattle Genetics.
MorphoSys and Bayer
In December 1999, MorphoSys and Bayer AG signed a wide-ranging antibody collaboration. In December 2005, the collaboration was extended by another five years, with a termination option after the first collaboration year.
MorphoSys and Schering
Since December 2001, MorphoSys had a strategic alliance with Schering AG. In December 2004, the collaboration was extended until the end of 2007.
Seattle Genetics and Bayer
In September 2004, Seattle Genetics announced that Bayer Pharmaceuticals licensed Seattle Genetics' proprietary ADC technology. The license provides Bayer with rights to utilize Seattle Genetics' ADC technology to link cell-killing drugs to antibodies against a specific tumor target selected by Bayer.
Bayer has paid Seattle Genetics a $2.0 million fee and, under the terms of the multi-year license agreement, has agreed to make progress-dependent milestone payments and pay royalties on net sales of resulting ADC...See full deal structure in Biomedtracker
Partners: MorphoSys AG Seattle Genetics, Inc.
Additional information available to subscribers only: